These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 12212016)

  • 1. Patient perceptions of prandial oral therapy for type 2 diabetes.
    Bonneville M; Colgin J; Nalesnick JA; Perez J; Wentz L
    Diabetes Educ; 2001; 27(5):669-77. PubMed ID: 12212016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes.
    Landgraf R; Frank M; Bauer C; Dieken ML
    Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S38-44. PubMed ID: 11063283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
    Owens DR
    Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-prandial vs. post-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated Type 2 diabetes: a randomized controlled clinical trial.
    Gerstein HC; Garon J; Joyce C; Rolfe A; Walter CM
    Diabet Med; 2004 Nov; 21(11):1200-3. PubMed ID: 15498086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.
    Owens DR; Luzio SD; Ismail I; Bayer T
    Diabetes Care; 2000 Apr; 23(4):518-23. PubMed ID: 10857945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
    Raskin P
    Diabetes Obes Metab; 2008 Dec; 10(12):1167-77. PubMed ID: 18494804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
    Bakiner O; Ertorer ME; Bozkirli E; Tutuncu NB; Demirag NG
    Acta Diabetol; 2009 Mar; 46(1):63-5. PubMed ID: 18825302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes.
    Owens D
    J Assoc Physicians India; 2001 Jan; 49 Spec No():54-61. PubMed ID: 11235607
    [No Abstract]   [Full Text] [Related]  

  • 10. Metformin/Repaglinide (PrandiMet) for type 2 diabetes.
    Med Lett Drugs Ther; 2009 Jun; 51(1313):41-3. PubMed ID: 19478691
    [No Abstract]   [Full Text] [Related]  

  • 11. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes.
    Moses RG; Gomis R; Frandsen KB; Schlienger JL; Dedov I
    Diabetes Care; 2001 Jan; 24(1):11-5. PubMed ID: 11194214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antidiabetic drug at every meal. Repaglinide is especially recommended for slender type 2 diabetic patients].
    Landgraf R
    MMW Fortschr Med; 2000 Jul; 142(28-29):29-30. PubMed ID: 10959157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control.
    Raskin P; Lewin A; Reinhardt R; Lyness W;
    Diabetes Obes Metab; 2009 Oct; 11(10):947-52. PubMed ID: 19531054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes.
    Moses R
    Expert Opin Pharmacother; 2000 Dec; 1(7):1455-67. PubMed ID: 11249478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes.
    Damsbo P; Marbury TC; Hatorp V; Clauson P; Müller PG
    Diabetes Res Clin Pract; 1999 Aug; 45(1):31-9. PubMed ID: 10499883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of repaglinide and metformin monotherapy as an initial therapy in Chinese patients with newly diagnosed type 2 diabetes mellitus.
    Fang FS; Gong YP; Li CL; Li J; Tian H; Huang W; Wang LC; Li L
    Eur J Endocrinol; 2014 Jun; 170(6):901-8. PubMed ID: 24694876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology and clinical experience with repaglinide.
    Massi-Benedetti M; Damsbo P
    Expert Opin Investig Drugs; 2000 Apr; 9(4):885-98. PubMed ID: 11060717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes.
    de Luis DA; Aller R; Cuellar L; Terroba C; Ovalle H; Izaola O; Romero E
    Diabetes Care; 2001 Oct; 24(10):1844-5. PubMed ID: 11574456
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus.
    Shapiro MS; Abrams Z; Lieberman N
    Isr Med Assoc J; 2005 Feb; 7(2):75-7. PubMed ID: 15729954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repaglinide in combination therapy.
    Moses R
    Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):33-8. PubMed ID: 12702006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.